Trial Profile
A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutations.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2011
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 21 Nov 2009 New trial record